G6PD deficiency in Plasmodium falciparum and Plasmodium vivax malaria-infected Cambodian patients

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Khim, Nimol ^a   Benedet, Christophe ^a   Kim, Saorin ^a   Kheng, Sim ^b   Siv, Sovannaroth ^b   Leang, Rithea ^b   Lek, Soley ^b   Muth, Sinuon ^b   Chea, Nguon ^b   Chuor, Char Meng ^b   Duong, Socheat ^b   Kerleguer, Alexandra ^a   Tor, Pety ^a   Chim, Pheaktra ^a   Canier, Lydie ^a   Witkowski, Benoit ^a   Taylor, Walter Rj ^b   Ménard, Didier ^a  

^a INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^b National Center for Parasitology Entomology and Malaria Control   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; PRIMAQUINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CAMBODIA; CAPILLARY ELECTROPHORESIS; CHILD; CLINICAL EVALUATION; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEALTH CARE POLICY; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HUMAN; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; MULTICENTER STUDY; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; PREVALENCE; QUANTITATIVE ASSAY; SCHOOL CHILD; SEX DIFFERENCE; CROSS-SECTIONAL STUDY; ENZYMOLOGY; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; MALARIA, FALCIPARUM; MALARIA, VIVAX; MIDDLE AGED; PARASITOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAMBODIA; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84878227305     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-171     Document Type: Article

References (33)

1. Global malaria mortality between 1980 and 2010: a systematic analysis. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD, Lancet 2012 379 413 431 10.1016/S0140-6736(12) 60034-8 22305225
2. WHO, Global plan for artemisinin resistance containment (GPARC) Geneva: World Health Organization 2011
3. The role of anti-malarial drugs in eliminating malaria. White NJ, Malar J 2008 7 Suppl 1 8 10.1186/1475-2875-7-S1-S8 19091042
4. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Wells TN, Burrows JN, Baird JK, Trends Parasitol 2010 26 145 151 10.1016/j.pt.2009.12.005 20133198
5. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI, Adv Parasitol 2013 81 133 201 23384623
6. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, Hogg MM, Battle KE, Padilla CD, Baird JK, PLoS Med 2012 9 1001339 10.1371/journal.pmed.1001339 23152723
7. The threat of artemisinin-resistant malaria. Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ, Wellems TE, Ringwald P, Newman RD, Plowe CV, N Engl J Med 2011 365 1073 1075 10.1056/NEJMp1108322 21992120
8. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. World Health Organization Malaria Policy Advisory Committee and Secretariat, Malar J 2012 11 424 23253143
9. WHO, World Malaria Report 2012 Geneva: World Health Organization 2012
10. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. World Health Organization, Bull World Health Organ 1989 67 601 611 2633878
11. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Beutler E, Blood 2008 111 16 24 10.1182/blood-2007-04-077412 18156501
12. Glucose-6-phosphate dehydrogenase deficiency. Cappellini MD, Fiorelli G, Lancet 2008 371 64 74 10.1016/S0140-6736(08)60073-2 18177777
13. The normal human female as a mosaic of X-chromosome activity: studies using the gene for G-6-PD-deficiency as a marker. Beutler E, Yeh M, Fairbanks VF, Proc Natl Acad Sci U S A 1962 48 9 16 10.1073/pnas.48.1.9 13868717
14. Hemolytic effect of therapeutic drugs. Clinical considerations of the primaquine-type hemolysis. Kellermeyer RW, Tarlov AR, Brewer GJ, Carson PE, Alving AS, JAMA 1962 180 388 394 10.1001/jama.1962.03050180034008a 14454972
15. Enzymatic deficiency in primaquine-sensitive erythrocytes. Alving AS, Carson PE, Flanagan CL, Ickes CE, Science 1956 124 484 485 13360274
16. The hemolytic effect of primaquine V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity. Dern RJ, Beutler E, Alving AS, J Lab Clin Med 1981 97 750 759 7229509
17. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T, Antimicrob Agents Chemother 2010 54 1762 1768 10.1128/AAC.01135-09 20194698
18. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE, Bull World Health Organ 1960 22 621 631 13793053
19. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Buchachart K, Krudsood S, Singhasivanon P, Treeprasertsuk S, Phophak N, Srivilairit S, Chalermrut K, Rattanapong Y, Supeeranuntha L, Wilairatana P, Brittenham G, Looareesuwan S, Southeast Asian J Trop Med Public Health 2001 32 720 726 12041544
20. Hemoglobin E and glucose-6-phosphate deficiency in the Khmer Air Force (Cambodia). Everett WD, Yoshida A, Pearlman E, Am J Trop Med Hyg 1977 26 597 601 268155
21. Primaquine sensitivity in Caucasians: hemolytic reactions induced by primaquine in G-6-PD deficient subjects. George JN, Sears DA, McCurdy PR, Conrad ME, J Lab Clin Med 1967 70 80 93 6027097
22. Hemolytic effects of standard single dosages of primaquine and chloroquine on G-6-PD-deficient caucasians. Pannacciulli I, Salvidio E, Tizianello A, Parravidino G, J Lab Clin Med 1969 74 653 661 5821522
23. [Systematic survey on hemoglobin E and glucose-6-phosphate dehydrogenase in Cambodia (October 1965-June 1966)] (in French). Goueffon S, du Saussay C, Bull Soc Pathol Exot 1969 62 1118 1132
24. Performance of the CareStart G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, Nhem S, Bouchier C, Tichit M, Christophel E, Taylor WR, Baird JK, Menard D, PLoS One 2011 6 28357 10.1371/journal.pone. 0028357 22164279
25. G6PD Viangchan (871G > A) is the most common G6PD-deficient variant in the Cambodian population. Louicharoen C, Nuchprayoon I, J Hum Genet 2005 50 448 452 10.1007/s10038-005-0276-2 16155737
26. Glucose-6-phosphate dehydrogenase (G6PD) mutations in Cambodia: G6PD Viangchan (871G > A) is the most common variant in the Cambodian population. Matsuoka H, Nguon C, Kanbe T, Jalloh A, Sato H, Yoshida S, Hirai M, Arai M, Socheat D, Kawamoto F, J Hum Genet 2005 50 468 472 10.1007/s10038-005-0279-z 16136268
27. [Frequency of G6PD deficiency in a group of preschool-aged children in a centrally located area of Cambodia] (in French). Monchy D, Babin FX, Srey CT, Ing PN, von Xylander S, Ly V, Busch Hallen J, Med Trop (Mars) 2004 64 355 358
28. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Louicharoen C, Patin E, Paul R, Nuchprayoon I, Witoonpanich B, Peerapittayamongkol C, Casademont I, Sura T, Laird NM, Singhasivanon P, Quintana-Murci L, Sakuntabhai A, Science 2009 326 1546 1549 10.1126/science.1178849 20007901
29. Focused Screening and Treatment (FSAT): a PCR-based strategy to detect malaria parasite carriers and contain drug resistant P. falciparum, Pailin, Cambodia. Hoyer S, Nguon S, Kim S, Habib N, Khim N, Sum S, Christophel EM, Bjorge S, Thomson A, Kheng S, Chea N, Yok S, Top S, Ros S, Sophal U, Thompson MM, Mellor S, Ariey F, Witkowski B, Yeang C, Yeung S, Duong S, Newman RD, Ménard D, PLoS One 2012 7 45797 10.1371/journal.pone.0045797 23049687
30. Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance. Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, Song J, Yeung S, Dondorp AM, Day NP, White NJ, White LJ, PLoS One 2012 7 37166 10.1371/journal.pone.0037166 22662135
31. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, Rowland M, PLoS One 2008 3 2861 10.1371/journal.pone.0002861 18682739
32. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, Baird K, Moyes C, Howes R, Ménard D, Bancone G, Winasti-Satyahraha A, Vestergaard LS, Green J, Domingo G, Yeung S, Price R, Malar J 2013 12 112 10.1186/1475-2875-12-112 23537118
33. Observations on the resistance in Hb E thalassaemia disease to induced infection with Plasmodium vivax. Ray RN, Chatterjea JB, Chaudhuri RN, Bull World Health Organ 1964 30 51 55 14122440